Ad hoc announcement pursuant to Art. 53 LR FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68.
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer
Ad hoc announcement pursuant to Art. 53 LR FDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2 Metastatic
The USPTO Patent Trial and Appeal Board (PTAB) has increasingly used its discretionary denial authority in recent years. Although the PTAB’s discretion under 35 U.S.C. § 314(a) and.
Asia-Pacific Neuroendocrine Tumors Market survey report covers company profiling of key players in the market, carefully analyzing their core competencies, and drawing a competitive landscape for the market. Company snapshot, geographical presence, product portfolio, and recent developments are taken into considerat.